drugset / Trial / NCT02089932

Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.

NCT02089932 ↗

Phase 4 Completed 60 enrolled Cairo University
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine in different dose levels as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Timeline

Start
2014-02
Primary completion
2015-04
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 25 ug Other
Subject Dexmedetomidine Other / unclassified 50 ug Other
Subject Dexmedetomidine Other / unclassified 75 ug Other
Background Bupivacaine Other / unclassified 25 ml Other

Indications

No indication recorded.